Credit Suisse Group set a €110.00 ($127.91) price objective on Merck KGaA (FRA:MRK) in a research note issued to investors on Wednesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other research firms also recently weighed in on MRK. Sanford C. Bernstein set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the company a buy rating in a research report on Monday, April 8th. Barclays set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the company a sell rating in a research report on Monday, April 8th. Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Tuesday, April 9th. UBS Group set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, April 1st. Finally, DZ Bank reiterated a neutral rating on shares of Merck KGaA in a research note on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of €101.05 ($117.50).

Merck KGaA stock traded up €0.66 ($0.77) during mid-day trading on Wednesday, reaching €91.76 ($106.70). The company’s stock had a trading volume of 366,117 shares. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: What is an overbought condition?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.